Department of Endocrinology and Nutrition, Hospital Clínic i Universitari of Barcelona, Barcelona, Spain.
Clin Transplant. 2010 Nov-Dec;24(6):E236-40. doi: 10.1111/j.1399-0012.2010.01261.x.
To describe the characteristics of metabolic control and beta-cell function in the long-term follow-up of patients with type-1 diabetes (T1D) who have undergone pancreas and kidney transplantation (PKTx).
Twelve patients (eight males/four females) with normal pancreas and kidney graft function for more than 15 yr were included. Patient age at the time of transplantation was 35.8 ± 6.9, with a duration of diabetes of 19.0 ± 4.6 yr and time on dialysis of 18.7 ± 12.4 months. In all the cases, bladder derivation was performed to drain exocrine secretion, with subsequent conversion to the intestinal tract in 42% of the patients. The functional evaluation was made at one, five, 10, and 15 yr after PKTx determining: glycosylated hemoglobin (HbA1c), oral glucose tolerance test (OGTT), measuring insulinemia, and anti-GAD antibody.
Comparing the results between one and 15 yr after transplantation: (i) no differences were observed in either HbA1c (4.68% vs. 4.76%) or basal glycemia (71 vs. 79 mg/dL), but an increase was seen in the area under the curve (AUC) of glucose (11,983 vs. 15,875 mg/dL/120', p = 0.02); (ii) a trend to a reduction in basal insulinemia (24 vs. 15 mU/L, p = 0.11) and a trend to a reduction in the AUC of insulinemia (8446 vs. 7057 mU/L/120', p = 0.22) were observed. The OGTT was normal in six patients, intolerant in two and diabetic in four patients. No variations were seen in insulin resistance (FIRI, QUICKI). Anti-GAD antibody became positive in one case.
The results of this study demonstrate that pancreas transplantation has long-term functional viability, being an essential strategy for the treatment of patients with T1D with end-stage renal failure. Nevertheless, lesser response to OGTT can be expected suggesting certain deterioration in the functional capability of the pancreas graft during follow-up.
描述 1 型糖尿病(T1D)患者胰腺和肾脏移植(PKTx)后长期随访中代谢控制和胰岛β细胞功能的特点。
纳入 12 例胰腺和肾脏移植物功能正常超过 15 年的患者(8 名男性/4 名女性)。移植时患者年龄为 35.8±6.9 岁,糖尿病病程 19.0±4.6 年,透析时间 18.7±12.4 个月。所有患者均采用膀胱引流来排出外分泌分泌液,随后有 42%的患者转为肠道引流。在 PKTx 后 1、5、10 和 15 年进行功能评估,测定糖化血红蛋白(HbA1c)、口服葡萄糖耐量试验(OGTT)、胰岛素血症和抗谷氨酸脱羧酶抗体。
将移植后 1 年和 15 年的结果进行比较:(i)HbA1c(4.68% vs. 4.76%)和基础血糖(71 vs. 79 mg/dL)均无差异,但葡萄糖曲线下面积(AUC)增加(11,983 vs. 15,875 mg/dL/120',p=0.02);(ii)基础胰岛素血症呈下降趋势(24 vs. 15 mU/L,p=0.11),胰岛素血症 AUC 呈下降趋势(8446 vs. 7057 mU/L/120',p=0.22)。6 例患者 OGTT 正常,2 例不耐受,4 例糖尿病。胰岛素抵抗(FIRI,QUICKI)无变化。抗谷氨酸脱羧酶抗体在 1 例患者中呈阳性。
这项研究的结果表明,胰腺移植具有长期的功能活力,是治疗终末期肾衰竭 1 型糖尿病患者的重要策略。然而,OGTT 的反应可能会减弱,提示在随访过程中胰腺移植物的功能能力出现一定程度的恶化。